



## Cardiovascular Disease and COVID-19

Guest Editor:

**Dr. Reinaldo Bulgarelli  
Bestetti**

Department of Medicine,  
University of Ribeirao Preto,  
Ribeirao Preto, Brazil

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editor

Dear Colleagues,

Cardiovascular disease is frequently found in patients with COVID-19. Arrhythmias, myocarditis, worsening heart failure, pulmonary embolism, cerebrovascular accidents, and peripheral vascular disease can affect patients infected with SARS-CoV-2 virus. In addition, cardiovascular disease has also been, although very rarely, associated with vaccination against this disease. Furthermore, the potential for cardiovascular involvement in long-COVID-19 is a real threat. Consequently, studies on the subjects raised above focusing on the immunological aspects of the disease are welcome. This Special Issue aims to provide knowledge to doctors at the frontline on the SARS-CoV-2-induced cardiovascular disease. Therefore, I am pleased to invite you to take part in this challenging task. For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: epidemiological, pathologic, clinical manifestations, subsidiary exam, clinical course, and treatment of SARS-CoV-2-induced cardiovascular disease.

I look forward to receiving your contributions.

Dr. Reinaldo Bulgarelli Bestetti  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)